CFO
ABMD

CVA Family Office’s Abiomed Inc ABMD Stock Holding History

CVA Family Office’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-90
Closed -$22K – 1023
2022
Q3 		$22K Hold
90
– – 0.01% 509
2022
Q2 		$22K Buy
90
+50
+125% +$13.5K 0.01% 526
2022
Q1 		$13K Buy
40
+10
+33% +$3.08K ﹤0.01% 643
2021
Q4 		$11K Buy
+30
New +$10.1K ﹤0.01% 638
2021
Q2 		– Sell
-30
Closed -$10K – 994
2021
Q1 		$10K Buy
+30
New +$9.6K ﹤0.01% 535

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

CVA Family Office's ABMD Position: Q4 2022 in Review

CVA Family Office sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 90 shares — an estimated $22K sold.

CVA Family Office first reported a position in ABMD in Q1 2021 and held it in 5 quarters. The position peaked at $22K in Q3 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • CVA Family Office reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • CVA Family Office sold 90 Abiomed Inc shares in Q4 2022, an estimated $22K.
  • CVA Family Office first reported a position in Abiomed Inc in Q1 2021 and held it in 5 quarters.
  • CVA Family Office's Abiomed Inc position peaked at $22K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on CVA Family Office's 13F filing for Q4 2022, filed 22 Feb 2023.